Development, Characterization, and Biological Evaluation of Clove Essential Oil Microemulsions
Applied Nano · 31.05.2026 · 7 (2) · 13
DOI: 10.3390/applnano7020013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Nano, online erschienen am 31.05.2026. Verfasst von José Nabor Haro-González und 3 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Clove essential oils (CEOs) are widely studied because of their biological potential; however, their applications are limited because of their water immiscibility. Microemulsions (MEs) can protect, deliver, and enhance the biological activities of CEOs, including their antioxidant and cytotoxic activities. In this research, the effects of ethanol as a cosurfactant and the polysorbate 80:cosurfactant mixture (Smix = 1:0, 9:1, 7:1, 5:1, 3:1, and 1:1) on the formation of CEO-MEs were evaluated via a pseudo-ternary phase diagram. After 35 days, all the systems produced clear, monodisperse, and thermodynamically stable MEs, characterized by average sizes below 25.6 nm and low polydispersity index values (
Zitieren
APA
Haro-González, J. N., Barbosa-Nuñez, J. A., Martínez-Velázquez, M., & Espinosa-Andrews, H. (2026). Development, Characterization, and Biological Evaluation of Clove Essential Oil Microemulsions. Applied Nano, 7(2), 13. https://doi.org/10.3390/applnano7020013
Vancouver
Haro-González JN, Barbosa-Nuñez JA, Martínez-Velázquez M, Espinosa-Andrews H. Development, Characterization, and Biological Evaluation of Clove Essential Oil Microemulsions. Applied Nano. 2026;7(2):13. doi:10.3390/applnano7020013
BibTeX
@article{HaroGonzlez2026,
author = {Haro-González, José Nabor and Barbosa-Nuñez, Jorge Alejandro and Martínez-Velázquez, Moisés and Espinosa-Andrews, Hugo},
title = {Development, Characterization, and Biological Evaluation of Clove Essential Oil Microemulsions},
journal = {Applied Nano},
year = {2026},
volume = {7},
number = {2},
pages = {13},
doi = {10.3390/applnano7020013}
}
EUVIMED